Fiscal 2011 Annual Report now available

The Offices of Technology Management are proud to report on the successes and activities of fiscal year 2011. The Offices' accomplishments are a direct result of the stellar faculty and research at the University of Illinois at Chicago.

Our mission is to encourage innovation, enhance research and facilitate economic development through the effective management, transfer, and commercialization of UIC technologies and intellectual property. Our focus is on ensuring the results of the outstanding research at UIC are successfully transferred outside the University to drive economic growth in the State of Illinois and benefit the general public.

In FY11 our Offices continued to advance our mission by bringing technologies to market that benefit society, return financial resources to the University and sustain innovation. A discovery made at UIC in collaboration with the National Institutes of Health is now making a difference in the lives of those living with HIV. Prezista, a novel protease inhibitor marketed by Johnson and Johnson, represented a turning point in HIV therapy when it launched in 2006. In FY11 the University earned more than $10 million in royalties on the drug. We are proud to see the Prezista license dramatically improving human health and making a financial impact for the University at the same time.

We sincerely thank you for your continued support of technology management and commercialization and we thank everyone who has participated in the technology transfer process. We look forward to continued success in FY2012.

 

View full FY2011 Annual Report.pdf

 

Fiscal 2011 Summary

 

Disclosures: 164

U.S. Patent Applications Filed: 183

U.S. Patents Issued: 23

Licenses & Options: 44

Start-Ups: 8

Patent Reimbursement: $361,960

Royalties Earned: $12,718,808

 

Top Royalty Generating Technologies

 

Multidrug Resistant Retroviral Protease Inhibitors: protease inhibitor compound known as Prezista and used to treat HIV-AIDS.

TICE BCG: for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, and for the prophylaxis of Ta and/or T1 papillary tumors following transurethral resection.

TIMS Elementary Math Program: an elementary school mathematics program for children in grades K-12.

 

Start-Ups

 

Avanti Biosciences, Inc.

Avanti Biosciences, an early stage biotech company, has secured an exclusive license to a technology developed from the College of Pharmacy.

Cell Biologics

Cell Biologics offers genetically modified and normal mouse primary endothelial cells and other mouse cell types based on proprietary techniques developed at the University of Illinois at Chicago. While genetically modified mice have proven to be a useful model for many human pathologies, culture of murine normal or genetically modified endothelial cells and other mouse primary cells are extremely beneficial to multidisciplinary, biomedically important, endothelial cell research in the areas of cell adhesion, angiogenesis, gene therapy and drug targeting. Cell Biologics is dedicated to the rapid development of significant basic and clinical research on the endothelium by saving investigators time, money and laboratory costs in the production of consistent normal and genetically modified cells in a timely and reproducible manner.

iMortal

iMortal is a startup company based on jointly developed intellectual property from UIC and the Mayo Clinic. The company is developing fall prevention technologies for the aging population from work done in the lab of Dr. Mark Grabiner, Professor of Kinesiology and Bioengineering. Dr. Grabiner and his colleagues have been studying how older adults fall in order to provide preventative training to quickly regain their balance before falling.

PAX Neuroscience

PAX is a solutions-based diagnostic company focused on the development and commercialization of innovative products that improve the quality of life and care for patients with depression and other mood disorders. The company has licensed an intellectual property portfolio that represents more than 25 years of extensive research by UIC's Dr. Mark Rasenick, an internationally recognized pioneer in G protein signalling and the molecular aspects of depression and antidepressant efficacy. Currently PAX is in the process of developing a two-step blood test that will be useful to quickly and reliably assess a response to antidepressant therapy by analyzing the movement of the Gs alpha protein found in human blood.

PicoLife

Founded by Dr. Farid Amirouche, Professor of Mechanical and Industrial Engineering at UIC, PicoLife is developing micropump technology that can be incorporated into medical devices. The company licensed intellectual property from the University related to micropumps that deliver small and accurate volumes of solutions. The company has investment from, and is working closely with, a large multinational pharmaceutical company on development of this technology.

Progenicyte Therapeutics

Related technologies that allow the harnessing of the power of human neural stem cells were licensed to Progenicyte Therapeutics. Jointly developed between UIC and the University of Central Florida, the technologies will be used to develop regenerative medicine products and stem cell-based research tools. Progenicyte Therapeutics combines the efforts of cell biologists, geneticists, and clinicians to create advancements toward effective treatment for a variety of malignant and non-malignant diseases.

SentiQuest

SentiQuest provides feature based sentiment analysis tools that analyze social media traffic on the internet. The technology was developed by Dr. Bing Liu, Professor of Computer Science. SentiQuest provides services to partners, including well-known opinion research firms.

Tianhe

Tianhe is a stem cell biotechnology company commercializing the inventions emanating from the labs of Drs. Zhao, Mazzone and Holterman within the Departments of Medicine and Surgery at the University of Illinois at Chicago. With operations in both Illinois and overseas, the company is pursuing the application of stem cells for the treatment of Type I diabetes through a clinical system which extracts the patient's own stem cells and utilizes them to re-educate the patient's faulty immune cells to prevent future immune response to the patient's own insulin producing cells.

 

 

 

 

 

 

print